Project Grant W81XWH2210282

The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...

Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received an $886,875 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective April 13, 2026, with completion scheduled for March 31, 2028. This R21-mechanism award supports research investigating phenotype-genotype relationships in tuberous sclerosis (TS), a rare...

The National Science Foundation (NSF) awarded a $999,255 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Tacit Therapeutics, Inc. The funding supports the development of a safe and effective RNA editing-based treatment for Dravet syndrome, a rare and devastating form of pediatric epilepsy. The project aims to replace defective sequences in the SCN1A gene, which is the primary genetic cause of Dravet syndrome, using a non-immunogenic RNA...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $148,942 to the Westfaelische Wilhelms-Universitaet Muenster in Germany to conduct research on identifying and characterizing the guanine nucleotide exchange factor (GEF) for the small GTPase Rheb as a novel target for treating tuberous sclerosis complex (TSC). The two-year award, running from July 1, 2024 to June 30, 2026, will support the university's...

Rutgers The State University of New Jersey, doing business as Rbhs-School of Nursing, was awarded a $783,077 Project Grant from the Defense Health Agency on May 1, 2023 to complete the project by April 30, 2026. The grant supports research titled "Defining the Cell Cycle Phase-Specific Regulation and Function of MTORC1 to Identify New Therapeutic Targets in TSC Tumors" under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...

This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $815,000.00 in funding to Albany Medical College to support transcellular mTOR signaling research between neurons and microglia and its implications in tuberous sclerosis complex (TSC). The grant, awarded on June 1, 2024, will support this biomedical research project over a 3-year period ending on May 31, 2027. As a private medical...

Federal Grant Award Summary Epicure Therapeutics, Inc. received a $1.5M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 16, 2026, with completion targeted for June 30, 2028. The company is developing a cell class-specific adeno-associated virus (AAV) gene therapy targeting SLC6A1-related neurodevelopmental disorder, a severe...

This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, provides $680,600 in federal funding to The Regents of the University of California, San Francisco through July 31, 2031. The award supports research to overcome medulloblastoma resistance to treatment using in vivo Perturb-Seq and preclinical therapeutics. The project addresses a critical clinical need, as medulloblastoma is the most common malignant brain...